Cooley advised emerging crop protection company Provivi on its $45.5 million series C-2 financing round led by Vivo Capital, with participation from returning shareholders. Provivi has developed a truly disruptive technological platform that enables the scalable production of environmentally friendly insect pheromone products. These products are able to naturally disrupt the mating cycle of insect pests and reduce the current overreliance upon non-sustainable synthetic insecticides. "The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico," said Dr. Pedro Coelho, cofounder and CEO of Provivi.